Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Yahoo17d
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
at a significantly lower cost — around $250 to $350 per month for tirzepatide, compared to Zepbound's list price of $1,059. With the official shortage over, the FDA has signaled it will crack ...
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
NBC DFW18d
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
Tirzepatide is the active ingredient in Zepbound ... Many insurance plans still don't cover drugs for weight loss, and some patients said prices under Eli Lilly's savings program and for its ...
FiercePharma8d
Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...
Citi downgrades Hims & Hers to Sell on valuation concerns
Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...
AOL15d
What is Compounded Tirzepatide? Here's What You Need to Know
If you’re taking tirzepatide for weight loss, you might find the drug isn’t covered by insurance. It comes with a hefty price tag, which can add up if you take the drug for a long time.